中芯国际 reported revenue of ¥38.64B for the period ended 2026-06-30, +19.4% year on year. Net income was ¥6.44B, a 16.7% net margin on a 23.2% gross margin. The largest revenue line is 集成电路晶圆代工 at 93% of the total. Free cash flow for the period was ¥5.04B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥38.64B | +19.4% |
| Gross profit | ¥8.95B | — |
| Operating income | ¥7.12B | — |
| Net income | ¥6.44B | +91.2% |
| Gross margin | 23.2% | Net margin 16.7% |
| Revenue Q/Q | +19.3% | — |
| Segment | Revenue | Share |
|---|---|---|
| 集成电路晶圆代工 | ¥35.86B | 92.8% |
| 其他 | ¥2.78B | 7.2% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥29.69B | 76.8% |
| R&D | ¥2.73B | 7.1% |
| SG&A | ¥1.58B | 4.1% |
| Tax & other | ¥0.68B | 1.8% |
| Item | Amount |
|---|---|
| Total assets | ¥389.96B |
| Total liabilities | ¥131.87B |
| Shareholders' equity | ¥258.09B |
| Equity / assets | 66.2% |
| Operating cash flow | ¥15.63B |
| Capital expenditure | ¥10.59B |
| Free cash flow | ¥5.04B |
| Cash conversion (OCF / net income) | 322% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
特锐德 ・ 神州泰岳 ・ 乐普医疗 ・ 南风股份 ・ 探路者 ・ 莱美药业 ・ 汉威科技 ・ 天海防务 ・ 安科生物 ・ ST豆神 ・ 鼎汉技术 ・ 华测检测
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies